Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies (SIGA) maintains this dedicated news hub for stakeholders tracking developments in biodefense therapeutics and public health preparedness. Access verified updates about the company's oral antiviral TPOXX, government contracts, and international health security initiatives.
This resource consolidates official announcements including regulatory milestones, strategic partnerships, and financial performance reports. Investors and public health professionals will find timely information on:
• TPOXX approvals and distribution updates
• Government procurement contracts
• Clinical research developments
• Financial disclosures and earnings
• Global health collaboration announcements
All content is sourced directly from company filings and press releases to ensure accuracy. Bookmark this page for efficient tracking of SIGA's progress in developing countermeasures against orthopoxviruses and other high-consequence pathogens.
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on March 4, 2021, at 4:30 PM ET to provide a business update. The call will feature CEO Dr. Phil Gomez, CFO Daniel Luckshire, and CSO Dr. Dennis Hruby. Participants can join the live webcast on SIGA's website, with a replay available for two weeks. SIGA focuses on health security, particularly through its lead product, TPOXX, an antiviral drug for smallpox. The company maintains a stockpile of 1.7 million doses in the Strategic National Stockpile.
SIGA Technologies (SIGA) announced a significant contract with the Public Health Agency of Canada for the purchase of oral TPOXX® valued at up to $33 million over five years. The initial commitment includes $3.4 million by March 31, 2021, and a cumulative $17.2 million by March 31, 2023. This contract follows a previous $14 million agreement with the Canadian Department of National Defence. SIGA expects Canadian regulatory approval for TPOXX in late 2021 or early 2022, enhancing its role in biodefense and public health preparedness.
On November 12, 2020, SIGA Technologies (SIGA) announced Dr. Dennis Hruby's participation in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference. The discussion, titled “COVID-19: Insights on an Epidemic Outbreak,” is scheduled for November 13, 2020, highlighting the importance of health security amidst the ongoing pandemic. Dr. Hruby emphasized the significance of TPOXX® (tecovirimat), an antiviral drug for smallpox, as a countermeasure against potential future pandemics. SIGA maintains a stockpile of 1.7 million TPOXX® courses under Project BioShield.
In Q3 2020, SIGA Technologies (SIGA) delivered approximately 134,000 courses of TPOXX® to the U.S. government, generating revenue of $41.4 million. Total revenues for Q3 were $44.3 million, a 35% increase compared to $32.9 million in Q3 2019. The company also reported net income of $31.6 million or $0.31 per share. Additionally, Canada plans to purchase up to 33,300 courses of TPOXX® over five years. SIGA repurchased 0.9 million shares for $5.6 million, totaling 3.7 million shares repurchased in 2020.
SIGA Technologies, Inc. (SIGA) will host a business update conference call on November 5, 2020, at 4:30 PM ET. CEO Dr. Phil Gomez and CFO Daniel Luckshire will present. A live webcast will be accessible via SIGA's website, and a replay will be available for two weeks. SIGA focuses on health security, with its leading product TPOXX® for smallpox treatment, approved by the FDA in July 2018. The U.S. government maintains a stockpile of 1.7 million courses under Project BioShield. For more details, visit www.siga.com.
SIGA Technologies (SIGA) announced a potential contract with the Public Health Agency of Canada (PHAC) for up to 33,300 courses of oral TPOXX (tecovirimat) over five years. The contract includes delivery of 18,500 courses by March 31, 2023, with an optional 14,800 courses afterward. This follows a prior contract from the Department of National Defence for 15,325 courses. SIGA plans to submit a marketing authorization application to Health Canada by the end of 2020, aiming for approval in 2021.
SIGA Technologies, a pharmaceutical company focused on health security, announced that CEO Dr. Phillip L. Gomez will participate in a fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. SIGA’s primary product is TPOXX® (tecovirimat), an antiviral approved for smallpox treatment. The U.S. maintains a stockpile of 1.7 million doses under Project BioShield.
In Q2 2020, SIGA Technologies reported total revenues of $40.3 million, a significant increase from $28.8 million in Q2 2019. Operating income improved to $3.9 million compared to a loss of $1.7 million a year earlier. The company successfully delivered 117,000 courses of TPOXX to the Strategic National Stockpile, generating $36.2 million in revenue. SIGA also expanded its international presence with a delivery of 2,500 courses to Canada. The company filed a Marketing Authorisation Application for oral tecovirimat, targeting approval in H2 2021.
SIGA Technologies, Inc. (SIGA) will host a webcast and conference call on August 6, 2020, at 4:30 P.M. ET to discuss a business update. Dr. Phil Gomez, CEO, and Daniel Luckshire, CFO, will participate. The call will be available on the company's website or by telephone. A replay will be provided for two weeks. SIGA focuses on health security, with TPOXX® as their lead product, approved for smallpox treatment. The company signed a contract with BARDA worth $51.6M for additional TPOXX development.
FAQ
What is the current stock price of Siga Technologie (SIGA)?
What is the market cap of Siga Technologie (SIGA)?
